Felmingham D, Brown D F, Soussy C J
Public Health Laboratory, Addenbrooke's Hospital, Cambridge, UK.
Diagn Microbiol Infect Dis. 1998 Aug;31(4):563-71. doi: 10.1016/s0732-8893(98)00053-4.
In the European Glycopeptide Susceptibility Survey 7078 Gram-positive isolates collected in 1995 from 70 centers in 9 countries of Western Europe were examined, using a standardized, quantitative susceptibility testing method. Of the 7078 isolates, 6824 (96.4%) were tested by the national coordinating centers. Teicoplanin (mode MIC 0.5 microgram/mL) was generally twice as active as vancomycin (mode MIC 1 microgram/mL) against Staphylococcus aureus (n = 2852). All isolates were susceptible to vancomycin (MIC < or = 4 micrograms/mL) and all but four to teicoplanin (MIC < or = 8 micrograms/mL); these four isolates were of intermediate susceptibility (MIC 16 micrograms/mL). With coagulase-negative staphylococci (n = 1444), the distribution of MIC of teicoplanin was wider than for vancomycin. Two and two-tenths percent of coagulase-negative staphylococci excluding Staphylococcus haemolyticus required 16 micrograms/mL teicoplanin for inhibition (intermediate) and 0.4% > or = 32 micrograms/mL (resistant). Among isolates of S. haemolyticus, 4.4% were of intermediate susceptibility (MIC 16 micrograms/mL) and 3.3% were resistant (MIC > or = 32 micrograms/mL) to teicoplanin. However, this species represented only 6.3% of the isolates of coagulase-negative Staphylococcus spp. Generally, teicoplanin (mode MIC < or = 0.12 microgram/mL) was four to eight times more active than vancomycin (mode MIC < or = 0.5 microgram/mL) against the 770 streptococcal isolates. Glycopeptide-susceptible Enterococcus spp. (n = 1695) were generally four times more susceptible to teicoplanin (mode MIC 0.25 microgram/mL) than to vancomycin (mode MIC 1 microgram/mL). Combined vancomycin and teicoplanin (VanA phenotype) resistance was observed more frequently (9.3%) in isolates of Enterococcus faecium than in Enterococcus faecalis (0.8%). Four isolates of unspeciated enterococci (1.4%) also expressed this resistance phenotype. Four isolates of E. faecium and four of E. faecalis expressed the VanB-type (low-level, vancomycin only) resistance. Spain was the only country not to submit resistant E. faecium strains while resistant E. faecalis isolates came only from Spain and Italy.
在欧洲糖肽药敏试验中,采用标准化的定量药敏试验方法,对1995年从西欧9个国家的70个中心收集的7078株革兰氏阳性菌进行了检测。在这7078株菌株中,6824株(96.4%)由国家协调中心进行检测。替考拉宁(MIC中位数为0.5微克/毫升)对金黄色葡萄球菌(n = 2852)的活性通常是万古霉素(MIC中位数为1微克/毫升)的两倍。所有菌株对万古霉素敏感(MIC≤4微克/毫升),除4株外对替考拉宁也敏感(MIC≤8微克/毫升);这4株菌株为中介敏感(MIC为16微克/毫升)。对于凝固酶阴性葡萄球菌(n = 1444),替考拉宁的MIC分布比万古霉素更宽。除溶血葡萄球菌外,2.2%的凝固酶阴性葡萄球菌需要16微克/毫升替考拉宁才能被抑制(中介),0.4%的菌株≥32微克/毫升(耐药)。在溶血葡萄球菌菌株中,4.4%对替考拉宁中介敏感(MIC为16微克/毫升),3.3%耐药(MIC≥32微克/毫升)。然而,该菌种仅占凝固酶阴性葡萄球菌菌株的6.3%。一般来说,替考拉宁(MIC中位数≤0.12微克/毫升)对770株链球菌的活性比万古霉素(MIC中位数≤0.5微克/毫升)高4至8倍。对糖肽敏感的肠球菌属(n = 1695)对替考拉宁(MIC中位数为0.25微克/毫升)的敏感性通常是对万古霉素(MIC中位数为1微克/毫升)的4倍。粪肠球菌菌株中观察到的万古霉素和替考拉宁联合耐药(VanA表型)比屎肠球菌(0.8%)更频繁(9.3%)。4株未分类的肠球菌(1.4%)也表现出这种耐药表型。4株粪肠球菌和4株屎肠球菌表现出VanB型(低水平,仅对万古霉素耐药)耐药。西班牙是唯一未提交耐药粪肠球菌菌株的国家,而耐药屎肠球菌菌株仅来自西班牙和意大利。